Review of BTKi for CLL and MCL

CME

A Year in Review: Expert Perspectives on Current and Emerging Data With BTK Inhibitors for CLL and MCL

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 05, 2023

Expiration: December 04, 2024

Ana Marin-Niebla
Ana Marin-Niebla, MD, PhD
Stephan Stilgenbauer
Stephan Stilgenbauer, MD

Activity

Progress
1 2
Course Completed

References

  1. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Eng J Med. 2022;386:2482-2494.
  2. Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized TRIANGLE trial by the European MCL Network. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract 1.
  3. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250-1260.
  4. Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687-399.
  5. Brexucabtagene autoleucel [prescribing information]. Santa Monica, CA: Kite; 2021.
  6. European Medicines Agency: brexucabtagene autoleucel. www.ema.europa.eu/en/medicines/human/EPAR/tecartus. Accessed November 29, 2023.
  7. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331-1342.
  8. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555-567.
  9. Minson AG, Hamad N, Cheah CY, et al. CAR T-cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: phase II TARMAC study. Blood. 2023;[Epub ahead of print].
  10. European Medicines Agency: brexucabtagene autoleucel. www.ema.europa.eu/en/medicines/human/EPAR/jaypirca. Accessed November 29, 2023.
  11. Pirtobrutinib [prescribing information]. Indianapolis, IN: Eli Lilly; 2023.
  12. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor preterated mantle cell lymphoma. J Clin Oncol. 2023;41:3988-3997.
  13. Jensen JL, Mato AR, Pena C, et al. The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022;13:20406207221101697.
  14. Cheah CY, Shah NN, Jurczak W, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results and subgroup analysis from the phase 1/2 BRUIN study with 2 years of survival follow-up. Presented at: 2023 International Conference on Malignant Lymphoma; June 13-17, 2023. Abstract 102.
  15. ASH Clinical News. AbbVie withdraws two accelerated ibrutinib approvals. ashpublications.org/ashclinicalnews/news/7217/AbbVie-Withdraws-Two-Accelerated-Ibrutinib. Accessed November 29, 2023.
  16. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
  17. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443.
  18. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43-56.
  19. European Medicines Agency: ibrutinib. www.ema.europa.eu/en/medicines/human/EPAR/imbruvica. Accessed November 29, 2023.
  20. Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;[Epub ahead of print].
  21. Hillmen P, Cairns DA, Bloor AJC, et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 631.
  22. Hillmen P, Pitchford A, Bloor A, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535-552.
  23. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial. J Clin Oncol. 2021;39:3441-3452.
  24. Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035-1045.
  25. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-332.
  26. Brown JR, Eichhorst BF, Lamanna N, et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 202.
  27. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389:33-44.
  28. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. v.1.2024. www.nccn.org. Accessed November 29, 2023.